Target Safety Assessment & Target Intelligence
Target Safety Assessment is essential for the success of your toxicology studies. Understanding your target early in drug development will ensure that you can de-risk your target, reduce the cost of your of toxicology studies and reduce the time spent in the preclinical stage.
At Metisox we can provide precision insights for your target(s) and you will receive a complete Target Profile. This includes target safety assessment, target intelligence, mechanistic driven drug discovery and identification of potential safety biomarker candidates. Our proprietary AI tools, machine learning and clinical data sources can search unexplored areas of biology to identify potential adverse effects, new targets for your pipeline as well as target repurposing options.
Metisox offers these as a complete package or as separate modules depending on your requirements and stage of your project.
Upcoming Webinar:
Enhance your gene expression analysis for your toxicology studies
26th May 2022 @4pm (GMT) / 11am (EST) / 8am (PST)
In this webinar you will learn about:
- Key considerations for gene expression analysis in toxicology studies
- Using gene expression analysis to understand and define compound toxicity
- How to identify precision insights from your gene expression data
Who should attend?
Professionals working in: pharmaceutical toxicology, chemical safety, preclinical safety, clinical development, medical biology, molecular biology
Learn about the liabilities that are potentially associated with your target to help accelerate your decision-making processes.
Download
Target Safety Assessment Sample Report
Target Safety Assessment Sample Brochure
Target Safety Assessment Sample Brochure
Learn more in our Target Safety Assessment Webinar Series:
Please click on one of our webinars below to learn more about our Mini-TSA and Full-TSA reports.
Target Safety Assessment Pipeline
Your TSA report will include the biology of target family, target function and involvement in human and animal diseases. The data is sourced from multiple types of data sources including several publicly available databases combined together with our proprietary SysWiz database. Metisox’s SysWiz database is utilised to extract multiomics intelligence; including mRNA and protein expression profiles, related proteins and intra- and inter- species variation.
Metisox has delivered TSA reports for targets from over 75% of all druggable families and looking forward to completing the whole family set with your target(s).
Your Target
Therapeutic indication & biological activity
Over 10 proprietary data sources
Over 30 public data sources
Datamining
In silico analysis
Biological network & pathway databases
Clinical trials & adverse effects databases
Literature text-mining
Manual & automated curation
Target analysis
Biological function & multiomics expression
Off-targets, isoforms & homologues
Genetic phenotype of animal and human
Pharmacological & ligand insights
Defined structural features
Cellular & tissue network analysis
Direct & indirect pathway effects of target modulation via protein-protein interactions and associated pathways
Toxicological Evaluation
Critical adverse effects observed in both preclinical studies and clinical trials
Target patient population
Toxicity profile & risk ranking
Adverse effects ranked based upon:
Severity
Observed frequency
Evidence
Relevance for patient population
“Outsourcing our Target Safety Assessment Reports to Metisox, for the past 5 years, has helped speed up our toxicology investigations as well as provide insightful mitigation plans that we were unable to deduce from our internal resources”
– Study Director, Toxicology
Safety biomarker candidates
Risk Mitigation Plan
Target repurposing options
Target Safety Assessment Reports (TSA Reports)
Metisox combines multiple data sources to deliver concise knowledge driven target safety assessment reports providing an intelligent safety profile of your target. The key output is a Risk Mitigation Plan that provides insights on your target and options to mitigate toxicology risks moving forward. This will include extensive knowledge for making informed decisions on your targets, ranking targets, de-risking strategies and/or designing investigative studies.
We offer three types of TSAs:
- Mini-TSA Report (Turnaround <5 days)
Provides insights rapidly for multiple targets following a screen
Useful for very early preclinical studies when there is limited data available - Standard TSA Report (Turnaround <20 days)
Provides detailed insights for your lead target
Actionable summary of safety concerns included in executive summary - Novel TSA Reports (Turnaround 5 – 20 days)
Utilises Metisox’s Precision Insights SysWiz database for predicting toxicology for novel targets
Deeper data mine compare to a Mini-TSA
Bulk discount offer – To learn more about our TSA Reports and/or request information on bulk discount options, please provide your details below:
Are you looking to increase the efficiency and knowledge base of your internal TSA Report writing?
SysWiz Database Subscription
Access to Metisox’s proprietary SysWiz database
Training sessions provided as standard
Individual(s) license or site-wide license available
Utilise cutting edge artificial intelligence tools
Bespoke database modules available upon request
2022 Discounts currently available
Click here for more information
Precision Insights 2022 Software
Early Access to Metisox’s proprietary Precision Insights Software
Full integration into your bioinformatics pipeline
Bespoke development of artificial intelligence tools
Multiomics data platform
Combine analysis of historical and new data sets
2022 Discounts currently available
Click here for more information